Israel's Taro completes $250M share buyback program
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback
Infographic: The Big Picture 2023 Sustainability Outlook
The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism
Taro Pharmaceutical Industries Ltd. completed a $250 million share buyback program which was announced in November 2016.
The Israeli pharmaceutical company bought back 2,493,378 ordinary shares at an average price of $100.28 per share.
